Skip to main content
Cosmos Health revenue hits $53.6 million, up 17.6%
Image for illustrative purposes only. Not a real photo.

Cosmos Health revenue hits $53.6 million, up 17.6%

By

Key points

  • Cosmos Health reported nine-month 2026 revenue of $53.6 million, up 17.6% year over year, although its net loss widened to $14.15 million.
  • The company reduced total debt by 33.8% to $12.83 million and increased stockholders' equity by 21.2% to $22.33 million, while fully settling its $8 million ATW convertible note.
  • Cana Laboratories expanded its contract manufacturing pipeline by 31% to more than 32.7 million units, as Cosmos Health continued efforts to strengthen its manufacturing operations and financial position.

Cosmos Health (NASDAQ:COSM) reported nine-month 2026 revenue of $53.59 million, up 17.6% from $45.57 million a year earlier, while its net loss widened to $14.15 million.

Third-quarter revenue declined to $16.68 million from $17.11 million, while the quarterly net loss narrowed to $5.25 million from $5.35 million and gross margin improved to 12.6% from 7.96% in the second quarter.

The nine-month loss included higher noncash interest and convertible-note valuation expenses, while total debt declined 33.8% to $12.83 million and stockholders' equity increased 21.2% to $22.33 million.

Following the announcement, Cosmos Health shares were unchanged at $2.85 in early trading on November 18, matching the previous session's closing price.

Meanwhile, Cana Laboratories increased its contract manufacturing pipeline by 31% since June to more than 32.7 million units across 11 therapeutic categories, representing over $20 million in estimated revenue and more than $18 million in implied gross profit.

Cosmos Health also fully settled its $8 million ATW convertible note approximately one year before maturity, launched a US subscription business that reached more than 12,500 active subscriptions by October 31, and completed a 1-for-20 reverse stock split effective November 13.


Frequently asked questions